These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8624121)

  • 1. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.
    Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH
    Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.
    Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH
    Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials in dementia with propentofylline.
    Kittner B; Rössner M; Rother M
    Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propentofylline for dementia.
    Frampton M; Harvey RJ; Kirchner V
    Cochrane Database Syst Rev; 2003; (2):CD002853. PubMed ID: 12804440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
    Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I
    Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.
    Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B
    Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials.
    Kittner B; De Deyn PP; Erkinjuntti T
    Ann N Y Acad Sci; 2000 Apr; 903():535-41. PubMed ID: 10818549
    [No Abstract]   [Full Text] [Related]  

  • 8. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia.
    Ringheim GE
    Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group.
    Kittner B
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine.
    Erkinjuntti T
    Eur J Neurol; 2002 Sep; 9(5):545. PubMed ID: 12220392
    [No Abstract]   [Full Text] [Related]  

  • 11. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)].
    Kapl D; Rudolphi KA
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Sep; 26(5):317-21. PubMed ID: 9931990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of introducing propentofylline for the treatment of dementia in Sweden.
    Wimo A; Witthaus E; Rother M; Winblad B
    Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citicoline in vascular cognitive impairment and vascular dementia after stroke.
    Alvarez-Sabín J; Román GC
    Stroke; 2011 Jan; 42(1 Suppl):S40-3. PubMed ID: 21164117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
    Gauthier S; Ferris S
    Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities.
    Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P
    Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
    Saletu B; Möller HJ; Grünberger J; Deutsch H; Rössner M
    Neuropsychobiology; 1990-1991; 24(4):173-84. PubMed ID: 2135708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors.
    Erkinjuntti T; Román G; Gauthier S
    Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dementia-related diseases. Propentofyllin--a neuroprotective glia cell modulator].
    Nervenarzt; 1998 Feb; 69(2 Suppl Propentofy):1-4. PubMed ID: 9532231
    [No Abstract]   [Full Text] [Related]  

  • 20. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia.
    Mielke R; Kittner B; Ghaemi M; Kessler J; Szelies B; Herholz K; Heiss WD
    J Neurol Sci; 1996 Sep; 141(1-2):59-64. PubMed ID: 8880694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.